Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

Phase 2

Completed

Conditions: Endometrial Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: bevacizumab

First Posted Date: 2007-08-09

Last Posted Date: 2017-08-01

Lead Sponsor: David O'Malley

Target Recruit Count: 38

Registration Number: NCT00513786

Locations: 🇺🇸
Ohio State University-Division of Gyn Oncology, Columbus, Ohio, United States

Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck

Phase 1

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Panitumumab
Drug: Carboplatin
Drug: Paclitaxel
Radiation: Intensity Modulated Radiation Therapy
Drug: 5-Fluorouracil
Drug: Docetaxel
Drug: Cisplatin

First Posted Date: 2007-08-08

Last Posted Date: 2017-03-01

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 34

Registration Number: NCT00513383

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery

Phase 3

Completed

Conditions: Stage IB Breast Cancer
Stage II Breast Cancer
Stage IIIA Breast Cancer
HER2/Neu Positive
Stage IA Breast Cancer

Interventions: Drug: Cyclophosphamide
Drug: Epirubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Procedure: Therapeutic Conventional Surgery
Biological: Trastuzumab

First Posted Date: 2007-08-08

Last Posted Date: 2019-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 280

Registration Number: NCT00513292

Locations: 🇺🇸
Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States
🇺🇸
Upper Valley Medical Center, Troy, Ohio, United States
🇺🇸
Siouxland Regional Cancer Center, Sioux City, Iowa, United States

and more 112 locations

Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer

Phase 2

Completed

Conditions: Advanced Ovarian Carcinoma
Primary Peritoneal Carcinoma
Ovarian Carcinosarcoma

Interventions: Drug: Avastin
Drug: Paclitaxel
Drug: Cisplatin

First Posted Date: 2007-08-06

Last Posted Date: 2017-07-02

Lead Sponsor: University of Oklahoma

Target Recruit Count: 20

Registration Number: NCT00511992

Locations: 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

Phase 2

Completed

Conditions: Locally Recurrent and Metastatic Breast Cancer

Interventions: Drug: AMG 386
Drug: AMG 386 Placebo
Drug: Bevacizumab
Drug: Paclitaxel

First Posted Date: 2007-08-03

Last Posted Date: 2015-10-29

Lead Sponsor: Amgen

Target Recruit Count: 228

Registration Number: NCT00511459

Locations: 🇬🇧
Research Site, Nottingham, United Kingdom

A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: AMG 951 (rhApo2L/TRAIL)
Drug: Bevacizumab
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2007-07-30

Last Posted Date: 2016-06-14

Lead Sponsor: Amgen

Target Recruit Count: 213

Registration Number: NCT00508625

Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Paclitaxel

First Posted Date: 2007-07-27

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT00508326

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer

Phase 2

Terminated

Conditions: Anaplastic Thyroid Cancer

Interventions: Drug: paclitaxel
Drug: CA4P
Drug: carboplatin

First Posted Date: 2007-07-26

Last Posted Date: 2014-06-09

Lead Sponsor: Mateon Therapeutics

Target Recruit Count: 80

Registration Number: NCT00507429

Locations: 🇮🇳
Kidwai Memorial Hospital, Bangalore, Karnataka, India
🇮🇳
Christian Medial College, Vellore, Tamil Nadu, India
🇮🇹
INT Napoli Fondazione Pascale, Napoli, Italy

and more 38 locations

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma

Phase 1

Terminated

Conditions: Uterine Cancer

Interventions: Drug: Imatinib Mesylate
Drug: Paclitaxel

First Posted Date: 2007-07-25

Last Posted Date: 2020-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 17

Registration Number: NCT00506779

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy

Phase 2

Terminated

Conditions: Uterine Neoplasms

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Paclitaxel

First Posted Date: 2007-07-23

Last Posted Date: 2011-09-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT00505492

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Washington School of Medicine, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy